Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Advisory Committees Risk Management

Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote

This article was originally published in RPM Report

  • Analysis

Executive Summary

Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.

Table

View full table

Advertisement

Related Content

Pink Sheet
“Do Not Compound” List One Step Closer, After FDA Names Advisors
Pink Sheet
Mystery Adcomm Revealed
Pink Sheet
Animal Rule Studies Should Be As Well-Designed As Human Clinical Trials, Panel Says
Pink Sheet
Conflict Over Conflicts: FDA Advisory Committee Rules May Be Ripe For Change
Pink Sheet
FDA “Flexibility” Presages Good Climate in 2012 for Approval Decisions, Shortage Situations
Pink Sheet
Collaring Wolfe: Propoxyphene Moves Activist Back To Public Supplicant Role
Pink Sheet
A Seat At The Drug Safety Table: Public Citizen’s Wolfe Joins FDA Advisory Committee
Pink Sheet
FDA Advisory Committees on the Brink: More Meetings, Fewer Members
Pink Sheet
The Role Of RiskMAPs: Fentora Shows Shift From Post-Market To Pre-Market
Pink Sheet
Panel Abuses Purdue Over OxyContin

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical Advisory Committees Risk Management
UsernamePublicRestriction

Register

PS081013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By